Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.
He, L., Zhang, M.Y., Cox, M., Zhang, Q., Donnell, A.F., Zhang, Y., Tarby, C., Gill, P., Subbaiah, M.A.M., Ramar, T., Reddy, M., Puttapaka, V., Li, Y.X., Sivaprakasam, P., Critton, D., Mulligan, D., Xie, C., Ramakrishnan, R., Nagar, J., Dudhgaonkar, S., Murtaza, A., Oderinde, M.S., Schieven, G.L., Mathur, A., Gavai, A.V., Vite, G., Gangwar, S., Poudel, Y.B.(2024) ACS Med Chem Lett 15: 189-196
- PubMed: 38352849
- DOI: https://doi.org/10.1021/acsmedchemlett.3c00456
- Primary Citation of Related Structures:
8S9H - PubMed Abstract:
Small molecule toll-like receptor (TLR) 7 agonists have gathered considerable interest as promising therapeutic agents for applications in cancer immunotherapy. Herein, we describe the development and optimization of a series of novel TLR7 agonists through systematic structure-activity relationship studies focusing on modification of the phenylpiperidine side chain. Additional refinement of ADME properties culminated in the discovery of compound 14 , which displayed nanomolar reporter assay activity and favorable drug-like properties. Compound 14 demonstrated excellent in vivo pharmacokinetic/pharmacodynamic profiles and synergistic antitumor activity when administered in combination with aPD1 antibody, suggesting opportunities of employing 14 in immuno-oncology therapies with immune checkpoint blockade agents.
Organizational Affiliation:
Research and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States.